Free Trial

Armata Pharmaceuticals (ARMP) SEC Filings & 10K Form

Armata Pharmaceuticals logo
$1.58 -0.07 (-4.25%)
Closing price 03/28/2025 04:10 PM Eastern
Extended Trading
$1.60 +0.02 (+1.27%)
As of 03/28/2025 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Armata Pharmaceuticals SEC Filings

DateFilerForm TypeView
03/20/2025
7:30 PM
Armata Pharmaceuticals, Inc. (Filer)
Armata Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/20/2025
7:32 PM
Armata Pharmaceuticals, Inc. (Filer)
Armata Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/12/2025
4:49 PM
Armata Pharmaceuticals, Inc. (Subject)
Armata Pharmaceuticals (Subject)
Innoviva, Inc. (Filed by)
Form SCHEDULE 13D/A
03/12/2025
4:14 PM
Armata Pharmaceuticals, Inc. (Filer)
Armata Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/19/2024
6:38 AM
Armata Pharmaceuticals, Inc. (Filer)
Armata Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2024
3:15 PM
Armata Pharmaceuticals, Inc. (Filer)
Armata Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/12/2024
6:07 AM
Armata Pharmaceuticals, Inc. (Filer)
Armata Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/03/2024
3:15 PM
Armata Pharmaceuticals, Inc. (Issuer)
Armata Pharmaceuticals (Issuer)
House David Duane (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/03/2024
3:15 PM
Armata Pharmaceuticals, Inc. (Filer)
Armata Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/26/2024
3:33 PM
Armata Pharmaceuticals, Inc. (Filer)
Armata Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/26/2024
6:50 AM
Armata Pharmaceuticals, Inc. (Filer)
Armata Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/19/2024
3:15 PM
Armata Pharmaceuticals, Inc. (Issuer)
Armata Pharmaceuticals (Issuer)
House David Duane (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
08/15/2024
4:00 PM
Armata Pharmaceuticals, Inc. (Filer)
Armata Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/13/2024
3:20 PM
Armata Pharmaceuticals, Inc. (Filer)
Armata Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/13/2024
3:15 PM
Armata Pharmaceuticals, Inc. (Filer)
Armata Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/28/2024
5:12 PM
Armata Pharmaceuticals, Inc. (Issuer)
Armata Pharmaceuticals (Issuer)
Kyme Pierre (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
05/07/2024
3:25 PM
Armata Pharmaceuticals, Inc. (Filer)
Armata Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Remove Ads

Related Companies and Tools


This page (NYSEAMERICAN:ARMP) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners